JOHNSON & JOHNSON is 35.3x more valuable than GENMAB A/S by market capitalization ($574.10 B vs $16.27 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GMAB | JNJ |
|---|---|---|
| Market cap | $16.27 B | $574.10 B |
| US-listed rank | #696 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | - | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 540 | 984 |
JOHNSON & JOHNSON is 35.3x more valuable than GENMAB A/S by market capitalization ($574.10 B vs $16.27 B).
Full pages: GENMAB A/S and JOHNSON & JOHNSON, or browse the full rankings.